Thrombopoietin Receptor Agonist Drug Class List

Drugs in Drug Class: Thrombopoietin Receptor Agonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Inc	ALVAIZ	eltrombopag choline	TABLET;ORAL	216774-001	Nov 29, 2023		RX	Yes	No	11,072,586		Y	Y
Teva Pharms Inc	ALVAIZ	eltrombopag choline	TABLET;ORAL	216774-002	Nov 29, 2023		RX	Yes	No	11,072,586		Y	Y
Teva Pharms Inc	ALVAIZ	eltrombopag choline	TABLET;ORAL	216774-003	Nov 29, 2023		RX	Yes	No	11,072,586		Y	Y

Market dynamics and patent landscape for Thrombopoietin receptor agonists (TRAs)

Last updated: April 25, 2026

Which drugs define the thrombopoietin receptor agonist landscape?

Thrombopoietin receptor agonists (TRAs) are platelet-production stimulators targeting the MPL (thrombopoietin receptor). The commercially established small molecule and protein modalities cluster into two therapeutics “sets”: peptidyl mimetics (second-generation MPL ligands) and small molecule MPL agonists.

Core, marketed agents

Agent	Modality	MPL target	Approved clinical focus (high level)	Key commercial positioning
Eltrombopag	Small molecule	MPL agonist	Thrombocytopenia due to chronic immune thrombocytopenia and chronic liver disease (including hepatitis C in prior approvals)	Oral convenience; long-term dosing patterns
Romiplostim	Peptide (Fc-fusion)	MPL agonist	Chronic immune thrombocytopenia	Weekly dosing; dose adjustment framework
Avatrombopag	Small molecule	MPL agonist	Thrombocytopenia in chronic liver disease (procedural platelet management)	Procedure-centric, short-course revenue model

These are the dominant revenue anchors in the TRA category through standard-of-care use in thrombocytopenia settings. (Drug label approvals and indications are reflected across FDA label documentation, e.g., eltrombopag and avatrombopag via FDA product pages and labeling.)

---

How does demand move, and what drives pricing and utilization?

TRA demand is primarily driven by three receipt channels: hematology care pathways (immune thrombocytopenia), hepatology/periprocedural pathways (chronic liver disease procedures), and off-protocol expansions (hospital-based platelet management where local standards and payer contracts shape use).

Demand drivers by use case

1) Chronic immune thrombocytopenia (ITP)

• Clinical need: chronic thrombocytopenia management with durable platelet response and avoidance of bleeding.
• TRA role: maintenance and rescue within ITP algorithms when steroids, IVIG, or other second-line agents underperform.
• Utilization pattern: dose titration, discontinuation trials, and long treatment horizons.

2) Chronic liver disease (CLD) and procedures

• Clinical need: reduce thrombocytopenia-related bleeding risk around planned interventions.
• TRA role: time-bounded administration around procedure dates.
• Utilization pattern: short courses; strong linkage to scheduling and local procedural protocols.

Market structure mechanics

• Hospital vs outpatient split: Romiplostim’s weekly administration creates a more clinic-administered flow, while eltrombopag/avatrombopag are oral, shifting site-of-care economics.
• Payer contracting: TRAs often face step edits, prior authorization triggers tied to platelet thresholds, and restrictions based on severity and treatment line.
• Safety monitoring cost: TRAs require baseline and ongoing platelet monitoring, driving workflow integration needs for prescribers.

Competitive pressure points

Pressure point	What it changes	Who benefits	Who faces margin risk
Switching between TRAs	Formulary churn and rebundled contracts	Agents with better payer access or simpler monitoring	Agents with narrow access
Oral convenience vs administration	Site-of-care cost allocation	Oral small molecules	Injectable weekly peptides
Procedure planning cycles	Short-course demand volatility	Brands with predictable procedural pathways	Products with lower protocol stickiness

---

What is the patent landscape’s “shape” for TRAs?

TRAs typically show a layered protection stack:

1. Core active ingredient patents (compound claims and compositions).
2. Formulation and polymorph coverage (particularly relevant to small molecules).
3. Use and dosing patents (indications, titration schemes, and administration regimens).
4. Manufacturing/process patents (less visible but important for challenges).

Across the category, many “earlier” patents have already expired or moved toward expiry, shifting the market to:

• new salt/polymorph/formulation lines,
• new dosing regimens,
• expanded indications and restricted subpopulations,
• and defense through patent thickets where the “best commercial fit” drug has multiple overlapping grants.

---

What patents and exclusivities anchored the category?

Eltrombopag (small molecule TRA): early entrant with layered protection

Eltrombopag is protected through a multi-year patent set reflecting compound claims and downstream formulation improvements. It launched as an oral alternative to peptide MPL agonists, and later expansions and regimen refinements supported continued use.

Key anchor evidence:

• FDA product records for eltrombopag confirm the existence of a dedicated labeled small molecule MPL agonist therapy. (FDA label pages: Eltrombopag drug product information.)

Romiplostim (peptide-Fc fusion): biopharmaceutical pathway and long-form protection

Romiplostim’s IP profile is typical for biologics: active and structural claims, manufacturing methods, and formulation. Biologic exclusivity timelines often dominate over single compound term expiration and can delay biosimilar entry depending on the protection stack.

Key anchor evidence:

• FDA product labeling for romiplostim provides the approved therapeutic identity used in the legal and commercial record. (FDA product page and prescribing information.)

Avatrombopag (small molecule TRA): procedural CLD focus

Avatrombopag’s commercial model is tightly tied to procedural platelet management in CLD. Patents tend to track small molecule claim sets and subsequent formulation improvements plus method-of-use protections tied to procedure timing and clinical setting.

Key anchor evidence:

• FDA product labeling confirms avatrombopag’s MPL agonist identity and procedural-oriented indications used in payer and clinical protocols. (FDA label page.)

---

Where are the patent barriers most likely to remain after first-generation term expiry?

Across TRA classes, the highest “sticking points” for challengers are typically:

• formulation-specific claims (salts/polymorphs for small molecules),
• method-of-use claims tied to titration and timing,
• and manufacturing process claims that affect generic/biosimilar development.

For biologic MPL agonists, “entry risk” often hinges on:

• the number of enforceable patents remaining in the thicket,
• whether any listed patents cover key features needed for a biosimilar product,
• and whether sponsors can establish a clean “no-infringement” or invalidity posture for target claims.

---

What does the patent landscape mean for generics and biosimilars?

Small molecule generic strategy (eltrombopag and avatrombopag)

Small molecule entry typically faces:

• compound and composition-of-matter barriers,
• salt/polymorph/formulation barriers,
• and method-of-use or dosing regimen claims.

Even when the active ingredient term narrows, secondary patents can still create meaningful delay if they cover:

• the specific form used commercially,
• the oral formulation characteristics,
• or prescribing regimens tied to specific clinical contexts.

Biologic/biosimilar strategy (romiplostim)

Biosimilar entry risk is more tightly coupled to:

• structural and sequence coverage,
• process claims,
• and the residual patent set for key functional characteristics.

If enforcement targets core structural or functional claims, a biosimilar sponsor’s design-around can be harder, pushing timelines outward.

---

How does competition play out on a lifecycle basis?

Phase 1: Growth and formulary establishment

• Initial adoption is driven by clinical need and guideline alignment.
• Reimbursement decisions and hospital protocols quickly shape “site stickiness.”

Phase 2: Differentiation by logistics and patient selection

• Oral small molecules gain share where outpatient management and administration simplicity matter.
• Injectable products gain share when weekly clinic workflows and established dosing titration protocols reduce operational friction.

Phase 3: Patent expiration, contract renegotiations, and new entrants

• As older patents approach expiry, pricing pressure rises where payers accept multiple interchangeable options.
• Patent thickets delay straightforward generic or biosimilar replacement and extend unit-price discipline.

---

What are the practical market implications for R&D investment?

Commercial target opportunities

Investable opportunities in this class typically cluster into:

• next-generation MPL agonists with better safety/tolerability profiles or more predictable platelet kinetics,
• patient selection innovations tied to responder phenotypes,
• and new combinations (where patentable method-of-use is viable).

IP strategy takeaways

For sponsors seeking to compete or defend:

• build around formulation and administration differentiation where it maps to clinical workflow,
• add method-of-use claims tied to monitoring and titration that reflect real-world dosing,
• and ensure patent filings cover manufacturing routes that remain robust under design-around.

---

Key takeaways

• The TRA category is anchored by eltrombopag, romiplostim, and avatrombopag, spanning oral small molecules and a peptide-Fc biologic.
• Market demand is strongest in ITP (longer maintenance cycles) and CLD procedural management (short-course, schedule-driven demand).
• Patent landscapes in TRAs typically remain layered: compound and composition, formulation/polymorph, and method-of-use/dosing claims.
• For competitive entry, the most durable barriers usually sit in secondary protection (especially formulation and dosing regimens) and, for biologics, in structural/functional and process patents.

---

FAQs

1) Which TRA segment is most driven by short-course demand?

Avatrombopag in chronic liver disease around procedures, where dosing is scheduled around interventions. (FDA product labeling.)

2) Does the TRA category rely more on site-of-care administration or prescribing?

It splits: romiplostim is clinic-administered weekly, while eltrombopag and avatrombopag are oral and shift economics toward outpatient prescribing. (FDA product labeling and administration modalities.)

3) Where do challengers typically lose time when seeking entry?

Where the commercially used form and dosing regimen are protected, especially formulation/polymorph and method-of-use layers for small molecules, and where structural/functional protection remains for biologics. (Patent thicket pattern anchored by FDA-labeled products and class protection behavior.)

4) What is the most important clinical monitoring driver for TRA utilization?

Platelet monitoring and dose titration, which affects workflow integration and payer prior authorization criteria. (FDA prescribing frameworks for TRA labels.)

5) What would be the clearest commercial differentiator for a new entrant?

Predictable platelet response with a dosing and safety profile that fits existing payer protocols and reduces monitoring friction, paired with enforceable, layered patent protection. (Mode-of-action and dosing-driven market behavior for TRAs.)

---

References

[1] U.S. Food and Drug Administration. Eltrombopag (drug label / product information). FDA.
[2] U.S. Food and Drug Administration. Romiplostim (drug label / product information). FDA.
[3] U.S. Food and Drug Administration. Avatrombopag (drug label / product information). FDA.